DANIEL PETRYLAK, M.D.

M.D.

Medical Oncology Physician

NPI: 1659387306IndividualAccepts Medicare

Specialties, Licenses & Credentials

Hematology & Oncology Physician

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

164174(NY)

Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

51405(CT)

CMS Specialties

PrimaryMEDICAL ONCOLOGY

Education

CLVLND CLINIC LERNER COLLEGE OF MED OF CASE WSTN RSV UNIVERSITY

Class of 1985

Research & Publications (20)

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

PMID 19380444·J Clin Oncol·2009

3-trial

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

PMID 19167733·J Urol·2009

2-rct

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.

PMID 19536904·Cancer·2009

3-trial

Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.

PMID 18501081·Clin Genitourin Cancer·2008

3-trial

Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.

PMID 18930256·J Urol·2008

3-trial

Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.

PMID 18501080·Clin Genitourin Cancer·2008

3-trial

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).

PMID 18006112·Lung Cancer·2008

3-trial

Treatment of metastatic urachal carcinoma in an elderly woman.

PMID 18097457·Nat Clin Pract Oncol·2008

5-case

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

PMID 18309951·J Clin Oncol·2008

6-review

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.

PMID 17960793·Cancer·2008

4-observational

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address: 35 PARK STREET, NP-4
NEW HAVEN, CT 06510
Phone: (203) 200-4822

Quick Facts

NPI: 1659387306
Entity Type: Individual
Gender: Male
Medicare: Accepted
Specialties: 2
Locations: 1
Years in Practice: 41
Publications: 20

Are you this provider?

Claim Your Profile